Proposed anti-cancer mechanisms for the combined protocols may involve enhanced expression of ERβ and PGR that subsequently inhibits ERα-mediated oncogenic effects with concurrent induction of cell cycle arrest and apoptosis in malignant enterocytes (31, 57, 59, 60). This evidence concerns the gene ESR2 and cancer.